Unusual 11 Mid-Day Movers 9/15: (AERI) (CLBS) (CBR) Higher; (UUUU) (ACST) (UWN) Lower

September 15, 2016 12:51 PM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) 51.0% HIGHER; reported the successful 90-day primary efficacy results of its 12-month Phase 3 “Mercury 1” clinical trial for its fixed-dose combination product candidate, Roclatan. The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and market leading prostaglandin analogue (PGA) latanoprost, all of which were dosed once daily in the evening.

Energy Fuels Inc. (NYSE: UUUU) 22.9% LOWER; announced that due to increased demand, it has entered into an amended and restated underwriting agreement with a syndicate of underwriters led by Cantor Fitzgerald Canada Corporation and Rodman & Renshaw a unit of H.C. Wainwright & Co., LLC, acting as co-lead underwriters and joint book-running managers, to increase the size of the previously announced bought deal to $13,050,000.

Acasti Pharma (Nasdaq: ACST) 21.0% LOWER; pulling back from a 125 percent gain on Wednesday after announcing that its bridging study for novel drug candidate CaPre? (omega-3 phospholipid) has successfully met its objectives, supporting Acasti's strategy to pursue the U.S. Food and Drug Administration's (FDA) 505(b)(2) regulatory pathway for approval.

Nevada Gold & Casinos (NYSE: UWN) 17.5% LOWER; reported Q2 EPS of ($0.01), versus $0.03 reported last year. Revenue for the quarter came in at $18.3 million, versus $15.9 million reported last year.

Misonix, Inc. (Nasdaq: MSON) 17.4% LOWER; announced that it filed a Form 12b-25 with the Securities and Exchange Commission indicating that Misonix likely will not be in a position to file its Annual Report on Form 10-K for the fiscal year ended June 30, 2016 within the 15-day extension period provided in Rule 12b-25(b) under the Securities Exchange Act of 1934.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) 16.4% HIGHER; announced that on September 14, 2016, it entered into Securities Purchase Agreements with several accredited investors for the sale of 4,449,153 shares of its common stock in private placements of $21 million.

Ciber, Inc. (NYSE: CBR) 15.6% HIGHER; said near an agreement to sell itself, according to market reports.

Lakeland Industries (Nasdaq: LAKE) 12.5% HIGHER; reported Q2 EPS of $0.20, $0.10 better than the analyst estimate of $0.10. Revenue for the quarter came in at $22.3 million versus the consensus estimate of $22.01 million.

Evine Live Inc. (Nasdaq: EVLV) 11.5% HIGHER; announced the execution of a definitive agreement to sell $10 million of common stock at $1.68 per share, which was priced at a 10 percent discount to the previous 15 day average of the Company’s stock, to investors (“Investors”) that include, among others, Mr. Tommy Hilfiger, Mr. Morris Goldfarb and Mr. Tommy Mottola. This initial investment is expected to close within a week.

CoLucid Pharmaceuticals (Nasdaq: CLCD) 11.4% HIGHER; Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of CoLucid Pharma following positive Phase III results from lasmiditan which de-risk additional development in acute migraine.

Sequans Communications S.A. (NYSE: SQNS) 10.5% LOWER; announced the pricing of an underwritten public offering of American Depositary Shares (ADSs), representing 15,151,520 ordinary shares, at a price of $1.65 per ADS, in an underwritten public offering under an effective shelf registration statement filed with the Securities and Exchange Commission.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Piper Jaffray, Cantor Fitzgerald, Rodman & Renshaw, Unusual 11 Mid-Day Movers, Charles Duncan, H.C. Wainwright

Add Your Comment